Cullinan Oncology announced that the first clinical data from its Phase 1 clinical study of CLN-619 in patients with advanced solid tumors will be presented at the 2023 American Society of Clinical Oncology Annual Meeting taking place in Chicago from June 2-6. "We are pleased to present our initial clinical findings for CLN-619 at ASCO 2023. CLN-619 is a novel, potential first-in-class antibody that binds to MICA and MICB, stress-induced ligands that engage the activating receptor NKG2D present on both innate and adaptive immune cells. MICA and MICB are expressed on a wide variety of solid tumors and hematological malignancies, and we believe CLN-619 has potential to treat a range of tumors," said Jeffrey Jones, MD, MPH, MBA, Chief Medical Officer, Cullinan Oncology. The details of the presentation include: A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CGEM:
- Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
- Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days
- Cullinan Oncology announces U.S. FDA clearance of IND for CLN-617
- Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
- Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
